Top of this page
Skip navigation, go straight to the content

The Company

  • UCB is a top five investor in UK pharmaceutical R&D*, investing over ¬£230 million in 2010
  • Globally UCB invests more than 20% of its sales revenue into R&D
  • In the UK, UCB's R&D, Commercial and Corporate functions are located in Slough, Berkshire
  • UCB employs around 600 staff in the UK, of whom about 400 are engaged in research and development activities
  • The company supplies over 40 UK-approved medicines.


* based upon data in the 2010 BIS R&D Scoreboard  (BIS = Department for Business, Innovation & Skills).

Key strengths

  • Close relationships with patients and the people who care for them
  • Cutting-edge research that combines biology and chemistry
  • Empowered, multidisciplinary and multinational teams
  • World-class partners across the value chain
  • A global player with a strong pipeline